|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/03/18 Aclaris Therapeutics, Inc. 10-Q 6/30/18 68:8.1M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 783K
2: EX-10.1 Material Contract HTML 351K
3: EX-10.2 Material Contract HTML 33K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
13: R1 Document and Entity Information HTML 40K
14: R2 Consolidated Balance Sheets HTML 99K
15: R3 Consolidated Balance Sheets (Parenthetical) HTML 38K
16: R4 Consolidated Statements of Operations and HTML 75K
Comprehensive Loss
17: R5 Consolidated Statements of Operations and HTML 22K
Comprehensive Loss (Parenthetical)
18: R6 Consolidated Statement of Stockholders' Equity HTML 50K
19: R7 Consolidated Statements of Cash Flows HTML 90K
20: R8 Organization and Nature of Business HTML 26K
21: R9 Summary of Significant Accounting Policies HTML 48K
22: R10 Acquisition of Confluence HTML 61K
23: R11 Fair Value of Financial Assets and Liabilities HTML 213K
24: R12 Property and Equipment, Net HTML 53K
25: R13 Accrued Expenses HTML 49K
26: R14 Stockholders' Equity HTML 29K
27: R15 Stock-Based Awards HTML 167K
28: R16 Net Loss per Share HTML 69K
29: R17 Commitments and Contingencies HTML 43K
30: R18 Related Party Transactions HTML 65K
31: R19 Agreements Related to Intellectual Property HTML 27K
32: R20 Income Taxes HTML 22K
33: R21 Segments HTML 179K
34: R22 Summary of Significant Accounting Policies HTML 66K
(Policies)
35: R23 Acquisition of Confluence (Tables) HTML 59K
36: R24 Fair Value of Financial Assets and Liabilities HTML 210K
(Tables)
37: R25 Property and Equipment, Net (Tables) HTML 53K
38: R26 Accrued Expenses (Tables) HTML 48K
39: R27 Stock-Based Awards (Tables) HTML 164K
40: R28 Net Loss per Share (Tables) HTML 70K
41: R29 Commitments and Contingencies (Tables) HTML 36K
42: R30 Related Party Transactions (Tables) HTML 60K
43: R31 Segments (Tables) HTML 175K
44: R32 Organization and Nature of Business (Details) HTML 26K
45: R33 Summary of Significant Accounting Policies HTML 30K
(Details)
46: R34 Summary of Significant Accounting Policies - HTML 27K
Recent Pronouncements (Details)
47: R35 Acquisition of Confluence - Summary of fair value HTML 38K
consideration (Details)
48: R36 Acquisition of Confluence - Supplemental pro forma HTML 32K
financial information (Details)
49: R37 Fair Value of Financial Assets and Liabilities HTML 52K
(Detail)
50: R38 Fair Value of Financial Assets and Liabilities - HTML 40K
by type (Details)
51: R39 Property and Equipment, Net (Details) HTML 47K
52: R40 Accrued Expenses (Details) HTML 42K
53: R41 Stockholders' Equity (Details) HTML 33K
54: R42 Stockholders' Equity - IPO, etc. (Details) HTML 43K
55: R43 Stock-Based Awards (Details) HTML 65K
56: R44 Stock-Based Awards - Option Activity (Details) HTML 79K
57: R45 Stock-Based Awards - RSUs (Details) HTML 44K
58: R46 Stock-Based Awards - Compensation (Details) HTML 46K
59: R47 Net Loss per Share (Details) HTML 34K
60: R48 Net Loss per Share - Anti-dilution (Details) HTML 27K
61: R49 Commitments and Contingencies (Details) HTML 42K
62: R50 Related Party Transactions (Details) HTML 47K
63: R51 Agreements Related to Intellectual Property HTML 45K
(Details)
64: R52 Income Taxes - Rate reconciliation (Details) HTML 25K
65: R53 Segments (Details) HTML 59K
67: XML IDEA XML File -- Filing Summary XML 118K
66: EXCEL IDEA Workbook of Financial Reports XLSX 64K
7: EX-101.INS XBRL Instance -- acrs-20180630 XML 2.02M
9: EX-101.CAL XBRL Calculations -- acrs-20180630_cal XML 138K
10: EX-101.DEF XBRL Definitions -- acrs-20180630_def XML 380K
11: EX-101.LAB XBRL Labels -- acrs-20180630_lab XML 1.07M
12: EX-101.PRE XBRL Presentations -- acrs-20180630_pre XML 686K
8: EX-101.SCH XBRL Schema -- acrs-20180630 XSD 125K
68: ZIP XBRL Zipped Folder -- 0001558370-18-006295-xbrl Zip 135K
| acrs_Ex10_2 |
Exhibit 10.2
First Amendment to License Agreement
The License Agreement effective as of December 31, 2015, between
|
A. |
Vixen Pharmaceuticals, a Delaware corporation, as assigned to and assumed by Aclaris Therapeutics Inc., having offices at 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087 (“RECIPIENT”) pursuant to the Stock Purchase Agreement signed by Vixen Pharmaceuticals and Aclaris Therapeutics Inc., dated March 24, 2015; and |
|
B. |
The Trustees of Columbia University in the City of New York, having an address at c/o Columbia Technology Ventures, 80 Claremont Avenue, Suite 4F, New York, New York 10027 (“Columbia”), |
a copy of the License Agreement is attached herewith as Schedule A (the “Agreement”), is hereby amended as follows:
|
1. |
Please amend Exhibit A by adding the following Section: |
|
IR |
Docket |
Patent/Application Title |
Patent/Application No. |
Filing Date |
Status |
|
[***] |
[***] |
[***] |
[***] |
[***] |
[***] |
|
2. |
This Amendment is effective as of June 27, 2018. |
|
3. |
All other terms and conditions of the Agreement shall remain in full force and effect, except as expressly amended herein. If there is any inconsistency or conflict between this Amendment and the Agreement, the provisions of this Amendment shall govern and control. This Amendment shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns. |
AGREED:
|
Recipient |
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
|
|
/s/ Neal Walker |
|
/s/ Scot G. Hamilton |
|
|
Printed Name: Neal Walker |
|
Printed Name: Scot G. Hamilton |
|
|
Title: President and CEO |
|
Title: AVP for CTV at Columbia |
|
|
Date:6/27/18 |
|
Date: 6/28/2018 |
|
|
|
|
TT 52520 |
|
Attachments:Schedule A – the Agreement
Page 1 of 1
Confidential and Proprietary
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/3/18 | 8-K | ||
| For Period end: | 6/30/18 | |||
| 6/27/18 | ||||
| 12/31/15 | 10-K, 10-K/A | |||
| 3/24/15 | ||||
| List all Filings | ||||